Clinical Trial Update: A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for ganetespib in ALK-positive non-small cell lung cancer, with the study status listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ganetespib (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED